摘要
目的 观察乳腺癌中CD44^＋／CD24^_/low的表达与临床病理特征的关系及其对预后的影响。方法应用双染免疫组织化学检测144例乳腺癌与30例乳腺良性肿瘤或正常乳腺组织中CD44^＋／CD24^_/low的表达，收集并分析患者的临床病理和随访资料。结果CD44^＋／CD24^_/low在乳腺良性肿瘤或正常乳腺中表达率为0％～8％，乳腺癌中表达率为0％～75％。67例（46．5％）乳腺癌患者CD44^＋／CD24^_/low表型的细胞〉10％，余77例（53．5％）≤10％。CD44^＋CD24^_/low的表达高低在淋巴结转移（P〈0．01）、病理分期（P〈0．01）、HER-2表达（P〈0．01）以及复发（P〈0．01）上差异有统计学意义。CD44^＋／CD24^_/low高表达的肿瘤复发时主要表现为远处转移，尤其是骨转移。CD44^＋／CD24^_/low高表达和低表达的5年无病生存率为65％和82％（P〈0．01），5年总生存率为68％和86％（P〈0．05），差异有统计学意义。结论CD44^＋／CD24^_/low的表达可能与乳腺癌的转移有关，有可能作为评估乳腺癌患者预后的参考指标。
Objective To detect the expression of CD44^＋/CD24^_/lowWin breast cancer cells, and investigate its relation with clinicopathologic features and prognosis. Methods Double-staining immunohistochemistry was used to detect the expression of CD44 ^＋/CD24^_/low on paraffin-embedded tissues of 144 patients and 30 normal or benign breast tissues. Moreover, the clinicopathologic features of patients with breast cancer and follow-up data were analyzed. Results The expression rate of CD44 ^＋/CD24^_/low ranged from 0% to 8% in normal or benign breast tissues,and from 0% to 75% in breast cancer tissues,respectively. The prevalence of CD44^ ＋/CD24^_/low cells in 67 tumors was 〉 10% , and ≤ 10% in the remaining 77 tumors. The expression levels of CD44 ^＋/CD24^_/low were significantly related with lymph node metastasis （P 〈 0.01 ）, pathological stage （ P 〈 0.01 ）, HER-2 expression （ P 〈 0.01 ） and recurrence （ P 〈 0.01 ）. Recurrences of tumors with high percentages of CD44^＋/CD24^_/low cells were mainly distant, particularly osseous metastasis. The 5-year disease-free survival rate in high and low expression of CD44 ^＋/ CD24^_/low was 65% and 82% respectively （P 〈 0.01 ）, and 5-year overall survival rats was 68% and 86% respectively （P 〈 0.05 ）. Conclusion The expression of CD44 ^＋/CD24^_/low was possibly associated with breast cancer metastasis and survival, and can be used a reference indicator to eveluate the prognosis of the patients with breast cancer.
出处
《中华实验外科杂志》
CAS
CSCD
北大核心
2009年第4期436-438,545,共4页
Chinese Journal of Experimental Surgery
基金
浙江省自然科学基金资助项目（Y207301）
